Pharmaceutical giants Eli Lilly and Novo Nordisk are expanding their obesity treatment portfolios beyond GLP-1 receptor agonists by investing in amylin-based therapeutics. These dual-action medications target additional metabolic pathways, offering patients enhanced weight loss and glycemic control. As the global obesity epidemic intensifies, amylin drugs represent a promising complementary strategy to existing therapies, potentially addressing treatment resistance and maximizing clinical outcomes in metabolic disease management.

Summary auto-generated by AI from the original publisher's content. Editorial standards.